View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Eurand Names Former Solvay Executive Jean-Louis Anspach President of US Pharmaceuticals Business

Eurand, a global specialty pharmaceutical company, today announced the appointment of Jean-Louis Anspach as president, Eurand Pharmaceuticals, Inc. (EPI). Anspach is a 25-year veteran of the specialty pharmaceutical and chemical industries and was most recently executive vice president, marketing at Solvay Pharmaceuticals (acquired by Abbott Laboratories in February 2010). He will be based at EPI’s commercial headquarters in Yardley, Pa.

“We are delighted to welcome Jean-Louis to the Eurand team,” said Gearoid Faherty, chairman and chief executive officer. “He combines strong managerial and leadership skills with a broad background in the specialty pharmaceutical sector that includes several successful product launches, most recently the FDA-approved formulation of another pancreatic enzyme product (PEP), Creon®. We believe his expertise and experience in developing and executing effective, impactful business plans and marketing strategies will serve Eurand well both for the ongoing launch of ZENPEP® – particularly at this time when only two FDA-approved PEPs are on the market – and for the future of our US commercial operations.”

“This is an exciting time to join Eurand, with ZENPEP’s growth accelerating,” Anspach said. “Achieving approximately 10% share of the pancreatic enzyme market just six months after launch is impressive and indicative of the potential of this franchise. I look forward to assuming leadership of the ZENPEP commercial efforts and helping the company build a successful branded specialty pharmaceuticals business in the US.”

Prior to joining Eurand, Anspach served as executive vice president, marketing for Solvay Pharmaceuticals. In this role, he successfully led the development and execution of business plans for the cardio-metabolic, neuroscience, gastroenterology, women’s health and specialized markets franchises. His 25-year career at Solvay included positions of increasing scope and responsibility in general management, marketing, sales, business development, investor relations and corporate finance.

Anspach received his ‘Ingenieur Commercial’ degree from the Universite Libre de Bruxelles (Belgium) and his MBA from the University of Wisconsin-Madison.

Eurand also announced that Michael Walters, executive vice president, sales and marketing, has resigned to pursue other opportunities. Walters joined Eurand in December 2007 as part of the acquisition of Source CF, a specialized pharmaceutical company focused on the needs of cystic fibrosis patients, physicians and caregivers.

“We are grateful for Mike’s many contributions to Eurand, most notably his leadership role in the establishment of our commercial operations in the US,” said Faherty. “We wish him all the best in his future endeavors.”

Dysphagia can affect many people throughout their lifetime and may compromise medication adherence.
For pharmaceutical manufacturers and healthcare providers, non-adherence to medication is a significant concern.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology